When Internal Bra Mesh Can Stay or Come Out

Internal-bra mesh usually does not need to be removed when it is causing no symptoms or concerning findings. In a November 13, 2023 report about updated labeling for nine BD mesh products, the FDA was described as not recommending reoperation or removal in asymptomatic patients. Removal becomes a consideration when infection, exposure, persistent fluid, tissue injury, severe pain, displacement, poor incorporation, or another complication makes leaving the material riskier than operating.

That communication included several GalaFLEX products but was not a universal instruction for every material or patient. It also did not establish a scheduled removal date for absorbable mesh.

Enter your surgery timing and symptoms; the checklist shows the level of follow-up the reported guidance supports.

Identify What Your “Internal Bra” Contains

“Internal bra” is a patient-facing name for a support technique, not one standardized product or operation. Support may come from the patient’s own tissue, internal sutures, absorbable synthetic mesh, a biologic scaffold such as acellular dermal matrix, permanent synthetic mesh, or a combination.

Material may reinforce the fold beneath the breast, support the lower breast, stabilize an implant pocket, or help correct implant displacement. Two patients told they received an internal bra can therefore have different materials in different anatomical locations.

GalaFLEX is described as a resorbable synthetic scaffold made from poly-4-hydroxybutyrate, or P4HB. Information about it cannot automatically be applied to DuraSorb, acellular dermal matrix, permanent mesh, or a tissue-and-suture technique.

Ask the operating practice or hospital for the complete operative report, product stickers, device records, and the mesh or scaffold’s brand, model, size, and lot information if available. The report may use terms such as mesh, scaffold, P4HB, PDO, ADM, sling, onlay, capsulorrhaphy, pocket reinforcement, or reinforcement of the inframammary fold.

Also establish whether you have a breast implant. Mesh explantation and breast-implant explantation are separate decisions. Removing one does not automatically require removing the other, although infection, rupture, tissue damage, or failure of the reconstructed pocket can affect both.

For a consultation, record the operation date, procedure type, product name, implant details, mesh location, when each symptom began, whether it is worsening, and any previous antibiotics, drainage, wound care, imaging, or revision procedures.

Different Materials Have Different Long-Term Behavior

There is no single absorption deadline or removal rule for everything described as an internal bra.

Material	Intended Behavior	Routine Removal	Reasons For Revision
Absorbable synthetic	Degrades over time	Usually no	Infection, exposure, fluid, pain, displacement, tissue injury
Biologic scaffold	Integrates or remodels, depending on product	Usually no	Infection, poor integration, exposure, deformity
Permanent synthetic	Remains in the body	No scheduled date	Infection, erosion, migration, folding, pain
Tissue and sutures	No mesh sheet is used	No mesh to remove	Suture, scar, wound, or implant-position problems

Absorbable Mesh Is Not Removed On A Timer

Absorbable mesh is intended to provide temporary reinforcement while degrading. Legal-news coverage has described GalaFLEX as intended to resorb in about 18 months, while other pages give differing estimates for various products. The exact product’s current labeling is more reliable than applying one online timeline to every scaffold.

An estimated absorption period is not a diagnostic cutoff. Firmness or a palpable area after that period does not prove that mesh remains intact or failed to degrade. Scar tissue, capsule, sutures, folded tissue, an implant edge, fluid, fat necrosis, displacement, or residual material can produce similar findings.

“Absorbable” also does not mean incapable of causing a problem before degradation finishes. Infection, exposure, poor incorporation, recurrent fluid, tissue injury, or a wound that will not heal may require treatment or removal sooner.

Biologic And Permanent Materials May Remain

Biologic scaffolds are made from processed human or animal tissue. Depending on the product, they may integrate with the patient’s tissue or be remodeled over time. The label “biologic” does not guarantee complete disappearance by a predictable date.

Permanent synthetic mesh is intended to remain. Permanence alone is not evidence of failure. A surgeon weighs evidence that the material is causing a problem against the pain, scarring, tissue loss, reduced support, deformity, and reconstructive work another operation could create.

The available evidence does not justify promises that absorbable mesh will leave permanently stronger tissue, provide lifelong support, prevent future sagging, or eliminate revision surgery.

Symptoms Determine Whether Evaluation Is Urgent

Patients without pain, infection, drainage, wound opening, rapid swelling, breast distortion, exposed material, or other concerning findings generally do not need preventive removal merely because mesh was used.

Persistent but nonrapid concerns should be assessed by a plastic surgeon. These include ongoing pain, recurrent swelling or fluid, worsening firmness, a folded or ridged palpable area, increasing asymmetry, delayed healing, implant displacement, or redness and drainage that improve and then return. Worsening firmness can also require evaluation for capsular contracture.

Seek prompt—and sometimes urgent or emergency—assessment for fever, pus or unusual drainage, rapidly increasing swelling, sudden bruising, severe or worsening pain, an opening incision, visible material, tissue discoloration, or skin and tissue breakdown. Rapid progression or systemic illness should not wait for a routine appointment.

Medical-legal health information reviewed for the evidence pack similarly advises evaluation for increasing pain, redness, fever, swelling, drainage, recurrent fluid, sudden bruising, open wounds, asymmetry, displacement, and skin changes. It also emphasizes that only a surgeon can decide whether removal is needed. See the medically reviewed breast-mesh overview.

Photograph a visible change if doing so will not delay care, note when it began, and tell the surgeon whether it is progressing. Provide the procedure date and product information if known. If the operating practice cannot be reached and symptoms appear urgent, do not delay assessment while searching for old records.

Surgeons Remove Mesh To Treat A Defined Problem

A symptom justifies evaluation but does not by itself prove that mesh caused it. Possible reasons for revision or partial or complete removal include:

• Persistent or recurrent infection involving implanted material
• An abscess, seroma, or hematoma requiring investigation or drainage
• Exposed mesh or material eroding into nearby tissue
• Folding, migration, or palpability associated with pain, skin pressure, deformity, or impaired healing
• Poor incorporation associated with fluid, motion, exposure, or support failure
• Wound breakdown, tissue necrosis, or contaminated nonviable tissue
• Persistent or worsening pain linked to an operative finding
• Implant displacement or breast deformity involving the support structure
• Implant rupture or failure of the reconstructed pocket

A legal-news review of adverse-event reports described palpable or folded material, infection, seroma, hematoma, wound or tissue breakdown, displacement, pain, deformity, and poor incorporation. Such reports can identify signals but do not prove that GalaFLEX caused an individual injury or show how frequently a complication occurs. Review the report and its limitations.

Lawsuits filed against Becton Dickinson in Rhode Island on April 28, 2026 included allegations involving GalaFLEX, severe pain, and subsequent removal or revision. These are plaintiffs’ allegations, not clinical findings that every recipient is at risk or needs explantation. Read the litigation report in context.

Law-firm pages also describe possible complications and implant-removal outcomes from selected reconstruction settings. They are not clinical guidelines. An implant-removal rate is not a mesh-removal rate, and findings from one reconstructive setting cannot be applied to every cosmetic operation or product. See the law firm’s overview.

Cosmetic dissatisfaction alone does not establish that mesh is causing harm. Asymmetry or settling can result from tissue stretching, scars, implant movement, recurrent sagging, or several factors together. Conversely, an acceptable appearance does not exclude infection or a wound problem.

Depending on the suspected cause, initial care may involve observation, antibiotics, wound treatment, fluid sampling, or drainage. If the complication persists, partial or complete removal may be considered. There is no universal rule favoring one approach.

Examination And Imaging Clarify The Cause

Evaluation starts with the operative history and a physical examination, not an assumption that the mesh must come out. The surgeon may assess the incision, skin, warmth, tenderness, drainage, breast shape, implant position, firmness, suspected fluid, and palpable edges or folds.

Ultrasound may be considered for a suspected fluid collection or focal palpable area. MRI or other breast imaging may be used when the implant, soft tissue, or extent of a problem needs further evaluation. Bloodwork, fluid sampling, and cultures may be considered when infection or a collection is suspected. These are possible tools, not automatic tests for every mesh recipient.

The decision depends on the material and its location, symptom severity, infection or fluid, skin integrity, tissue viability, incorporation, implant condition, scar tissue, prior operations, radiation history, available healthy tissue, and the patient’s reconstructive goals.

If the original surgeon is unavailable or the reason for the proposed operation remains unclear, consider a second opinion from a board-certified plastic surgeon experienced in breast revision or reconstruction.

Ask what finding implicates the mesh, what other causes remain possible, whether nonoperative treatment is reasonable, and what would make surgery necessary. If removal is proposed, ask whether it would be partial or complete, whether the implant could remain, what support would be needed afterward, and whether reconstruction could require multiple operations.

Mesh And Implant Removal Are Separate Operations

Mesh explantation removes some or all of a scaffold. Breast-implant explantation removes the implant. Implant exchange replaces it with another implant. Debridement removes damaged, dead, contaminated, or infected tissue, while pocket reconstruction repairs or reshapes the space holding the implant.

A surgeon may sometimes remove or revise mesh while preserving an intact implant. Implant preservation cannot be promised before infection, tissue condition, pocket contamination, and operative findings are assessed.

Both components may require treatment when there is extensive infection, implant rupture, severe soft-tissue damage, a contaminated pocket, major displacement with support failure, or broader reconstructive failure. Surgery may combine drainage, debridement, mesh removal, implant removal or replacement, and pocket repair.

Possible consequences include additional scars, postoperative pain, reduced internal support, asymmetry, tissue loss, altered breast shape, delayed implant replacement, staged reconstruction, or further operations. The operative plan should distinguish what must be treated immediately, what material can safely remain, and what support will be needed afterward.

FDA Status Does Not Create An Automatic Removal Rule

FDA clearance for general soft-tissue reinforcement is not the same as clearance or approval specifically for breast augmentation or a breast lift.

On November 13, 2023, the Regulatory Affairs Professionals Society reported that the FDA had not determined the safety and effectiveness of surgical mesh for breast surgery and that no surgical mesh was then cleared or approved specifically for breast use, including augmentation or reconstruction. The communication concerned updated warnings and precautions for nine BD products, including GalaFLEX Lite Scaffold, GalaFLEX Scaffold, GalaFLEX 3D Scaffold, and GalaFLEX 3DR Scaffold. Read the RAPS account of the FDA communication.

The same report said the FDA was not recommending reoperation or removal in asymptomatic patients. Those positions are not contradictory. Lack of breast-specific authorization supports caution and the need for stronger evidence, but it does not mean every patient already implanted with mesh benefits from another operation.

Off-label use means a legally marketed product was used in a way not included in its specific cleared or approved labeling. It does not by itself prove that the product is defective, that it caused a symptom, that a complication exists, or that removal is safer than observation.

The evidence supplied here does not include a current primary FDA document or current manufacturer instructions for use. The November 2023 statements are therefore historical, product-specific reporting rather than confirmation of every product’s regulatory status or labeling in 2026. Patients and clinicians should verify current communications and labeling for the exact product.

Breast-specific long-term evidence remains limited across the products and techniques grouped under “internal bra.” The available sources do not provide a reliable overall complication rate or mesh-removal rate. Adverse-event reports lack a known denominator and may be incomplete; lawsuits contain allegations rather than controlled clinical evidence.

For an asymptomatic patient, the practical next step is to identify the product and continue individualized follow-up rather than arrange preventive removal. Persistent pain, fluid, firmness, displacement, asymmetry, or wound concerns call for plastic-surgery assessment. Fever, drainage, rapid swelling, exposed material, severe or escalating pain, an opening wound, or tissue breakdown calls for prompt medical care.